Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies for cardiovascular disease and cancer, has issued a shareholder update detailing potential merger and asset sale strategies. The update, authored by CEO Jim Joyce, addresses the company's efforts to overcome financial hurdles following a failed Nasdaq uplist attempt.
Joyce, who previously founded Aethlon Medical and led the development of the Hemopurifier—a device recognized by TIME magazine as a top invention—described Sigyn's lead candidate, CardioDialysis. This therapy targets cholesterol-transporting lipoproteins and inflammatory molecules, aiming to treat cardiovascular disease, sepsis, and traumatic brain injury. Unlike current lipoprotein apheresis, which is limited to fewer than 60 U.S. centers, CardioDialysis is designed for use on dialysis machines at over 7,500 clinics nationwide.
The company's challenges stem from its public listing status. Sigyn became public via a merger with an OTC company but failed to secure a Nasdaq uplist. Joyce explained that a firm commitment offering led by a FINRA member broker-dealer was derailed by a regulatory catch-22: Nasdaq required review of investors before an effective SEC registration statement, while the SEC required Nasdaq listing approval first. The registration statement was eventually withdrawn.
To navigate forward, Joyce highlighted strategies from a January 15th shareholder update, including the sale of certain assets and a potential merger with a Nasdaq-listed company at risk of failing the $5 million minimum market value of listed securities (MVLS) requirement. Joyce noted that the company's TBI indication has emerged as a valuable asset for such transactions.
The update also referenced Spectral Medical, a Toronto Stock Exchange company developing the PMX hemoadsorption device for sepsis, which has a market value of approximately $300 million. Joyce noted that CardioDialysis has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators, potentially positioning it as a broader-spectrum alternative.
As of March 11, 2026, Sigyn has 2,330,042 shares outstanding. The company's pipeline also includes ImmunePrep for immunotherapeutic antibody delivery, ChemoPrep for targeted chemotherapy, and ChemoPure to reduce chemotherapy toxicity.
